Clinical trial
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
NCT02750514
Study timeline
Study start (actual)2016-05-09Date precision: day
Registry last updated2021-03-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Advanced Cancerunresolved
Interventions
NivolumabBIOLOGICAL
DasatinibDRUG · verified · RxNorm: dasatinib
RelatlimabBIOLOGICAL
IpilimumabBIOLOGICAL
BMS-986205DRUG
Sponsors & collaborators
Bristol-Myers Squibblead sponsor
Mapped research locations
BostonMassachusetts, United States3Los AngelesCalifornia, United States3PhiladelphiaPennsylvania, United States2BaltimoreMaryland, United States2MadridSpain2MilanItaly2New YorkNew York, United States1HoustonTexas, United States1DallasTexas, United States1St LouisMissouri, United States1NashvilleTennessee, United States1SeattleWashington, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02750514 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.